Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Boyle, E. M.; Maclachlan, K.; Taylor, J.; Watts, J. M.; Lu, S. X.; Coffey, D. G.; Bolli, N.; Papaemmanuil, E.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • SMYD2 regulates chromatin modifier KMT2D in ER+/PIK3CA mutant breast cancer
    Meeting Abstract

    Blawski, R.; Sallaku, M.; Guo, X.; Kittane, S.; Scaltriti, M.; Luo, M.; Toska, E.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • SUV39H1 disruption enhances the persistence and anti-tumor efficacy of CD28-costimulated human CAR T cells
    Meeting Abstract

    Jain, N.; Zhao, Z.; Koche, R.; Gozlan, Y.; Brocks, D.; Raveh-Sadka, T.; Wells, D.; Dobrin, A.; Shi, Y.; Lopez, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A human pluripotent stem cell derived differentiation model for the study of normal and transformed sympatho-adrenal progenitors
    Meeting Abstract

    Van Haver, S.; Fan, Y.; Van Loocke, W.; De Preter, K.; Kentsis, A.; Studer, L.; Roberts, S.; Speleman, F.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Plinabulin after autologous hematopoietic cell transplant to decrease duration of neutropenia and improve quality of life peri-transplant
    Meeting Abstract

    Shah, G.; Shulman, L.; Hanley, D.; Chung, D.; Datta, A.; Dhar, P.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: A retrospective study of 34 patients highlighting the need for consensus criteria
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Jaffer-Sathick, I.; Rossi, A.; Salvatore, S.; Landau, H.; Lahoud, O.; Korde, N.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save